【 中文摘要 】本發明屬于抗癌藥物技術領域，公開了一種CD47抗體聯合鈉鉀ATP酶抑制劑的藥物組合在腫瘤治療中的應用，具體公開了鈉鉀ATP酶抑制劑在制備促進CD47抗體吞噬作用的産品中的應用。本發明基于前期藥物篩選結果，首次發現了鈉鉀ATP酶抑制劑藥物(哇巴因、地高辛)顯著增效CD47抗體的吞噬效應，而在篩選結果中其他抗腫瘤化合物不具有此效應。本發明以哇巴因、地高辛這一類鈉鉀ATP酶抑制劑和CD47抗體組合藥物提升巨噬細胞吞噬功能爲主導，将進一步激活後續抗腫瘤免疫反應。

【 英文摘要 】The invention belongs to the technical field of anti-cancer drugs, discloses an application of a drug combination of a CD47 antibody and a sodium-potassium ATPase inhibitor in tumor treatment, and particularly discloses an application of the sodium-potassium ATPase inhibitor in preparation of a product for promoting phagocytosis of the CD47 antibody Based on the early drug screening results, the present invention discovered for the first time that sodium-potassium ATPase inhibitor drugs (ouabain, digoxin) significantly enhance the phagocytosis effect of CD47 antibodies, but other anti-tumor compounds do not have this effect in the screening results. The present invention is dominated by the combination of sodium-potassium ATPase inhibitors such as ouabain and digoxin and CD47 antibodies to improve the phagocytosis function of macrophages, which will further activate subsequent anti-tumor immune reactions.

[ 英文標題 ]

【 技術功效 】

【技術分類】

【行業分類】

【 首項權利要求-原文 】

1.鈉鉀ATP酶抑制劑在制備促進CD47抗體吞噬作用的産品中的應用。

【 首項權利要求-翻譯 】

1. Application of sodium potassium ATP enzyme inhibitor in preparing product for promoting phagocytosis of CD47 antibody.